JP2024531663A5 - - Google Patents

Info

Publication number
JP2024531663A5
JP2024531663A5 JP2024515606A JP2024515606A JP2024531663A5 JP 2024531663 A5 JP2024531663 A5 JP 2024531663A5 JP 2024515606 A JP2024515606 A JP 2024515606A JP 2024515606 A JP2024515606 A JP 2024515606A JP 2024531663 A5 JP2024531663 A5 JP 2024531663A5
Authority
JP
Japan
Prior art keywords
time spent
mouse
compound
animal model
social
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024515606A
Other languages
English (en)
Other versions
JP2024531663A (ja
JP7765613B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from KR1020220113977A external-priority patent/KR102560630B1/ko
Priority claimed from PCT/KR2022/013519 external-priority patent/WO2023038456A1/ko
Publication of JP2024531663A publication Critical patent/JP2024531663A/ja
Publication of JP2024531663A5 publication Critical patent/JP2024531663A5/ja
Application granted granted Critical
Publication of JP7765613B2 publication Critical patent/JP7765613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

２．自閉症動物モデルにおける化合物の社会性改善効果及び認知改善効果の確認
発達障害の表現型の１つである社会性の欠如に対する本発明の化合物の治療効果を確認するために、ＶＰＡ（Ｖａｌｐｒｏｉｃ ａｃｉｄ）誘導自閉症動物モデルを用いてスリーチャンバーテスト（ｔｈｒｅｅ ｃｈａｍｂｅｒ ｔｅｓｔ）を行った。チャンバー滞在時間（ｃｈａｍｂｅｒ ｄｕｒａｔｉｏｎ）は、ストレンジャー（ｓｔｒａｎｇｅｒ、マウスへの滞在時間）、エンプティ（ｅｍｐｔｙ、空きスペースへの滞在時間）、センター（ｃｅｎｔｅｒ、中央スペースへの滞在時間）として示され、空きスペースよりもマウスへの滞在時間が多いと、社会性があると判断した。
JP2024515606A 2021-09-08 2022-09-08 新規化合物及びその情緒行動障害の治療用途 Active JP7765613B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20210119526 2021-09-08
KR10-2021-0119526 2021-09-08
KR1020220113977A KR102560630B1 (ko) 2021-09-08 2022-09-08 신규 화합물 및 이의 정서행동장애 치료 용도
PCT/KR2022/013519 WO2023038456A1 (ko) 2021-09-08 2022-09-08 신규 화합물 및 이의 정서행동장애 치료 용도
KR10-2022-0113977 2022-09-08

Publications (3)

Publication Number Publication Date
JP2024531663A JP2024531663A (ja) 2024-08-29
JP2024531663A5 true JP2024531663A5 (ja) 2025-07-25
JP7765613B2 JP7765613B2 (ja) 2025-11-06

Family

ID=85506826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515606A Active JP7765613B2 (ja) 2021-09-08 2022-09-08 新規化合物及びその情緒行動障害の治療用途

Country Status (3)

Country Link
US (1) US20240417385A1 (ja)
JP (1) JP7765613B2 (ja)
WO (1) WO2023038456A1 (ja)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2356891C9 (ru) 2002-05-16 2010-03-27 Байер Кропсайенс Аг Производные пиридинкарбоксамида и их соли для применения в качестве инсектицида
DE10346245A1 (de) * 2003-10-06 2005-04-28 Bayer Cropscience Gmbh Verfahren zur Herstellung von Acylharnstoffderivaten, Salze dieser Acylharnstoffderivate und deren Verwendung als Schädlingsbekämpfungsmittel
CN102532062B (zh) * 2010-12-08 2013-12-04 上海工程技术大学 一种苯甲酰脲化合物及其合成方法
JP2019533022A (ja) * 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用

Similar Documents

Publication Publication Date Title
Santana et al. Histone modifications in Alzheimer’s disease
Tanti et al. Region‐dependent and stage‐specific effects of stress, environmental enrichment, and antidepressant treatment on hippocampal neurogenesis
Alberini et al. The regulation of transcription in memory consolidation
Cowansage et al. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity
El Agha et al. Walking along the fibroblast growth factor 10 route: a key pathway to understand the control and regulation of epithelial and mesenchymal cell‐lineage formation during lung development and repair after injury
Cohen et al. Amygdalar expression of the micro RNA miR‐101a and its target Ezh2 contribute to rodent anxiety‐like behaviour
Horio et al. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine‐induced cognitive deficits in mice
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
Riolo et al. Molecular genetic features of cerebral cavernous malformations (CCM) patients: an overall view from genes to endothelial cells
JP2019525984A5 (ja)
ATE318272T1 (de) Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
JP2015527402A5 (ja)
ATE309797T1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
ES386601A1 (es) Un procedimiento de resolucion de 2-(oclorofenil) - 2- me- tilamino-ciclohexanona racemica.
Hasegawa et al. Structural dynamics and stability of corticocortical and thalamocortical axon terminals during motor learning
MX2019004253A (es) Proceso para la preparacion de acidos (1r,3r) - y (1s,3s)-2,2-dihalo-3-(fenilo sustituido) ciclopropanocarboxilicos.
Tian et al. Lack of antidepressant effects of low-voltage-sensitive T-type calcium channel blocker ethosuximide in a chronic social defeat stress model: comparison with (R)-ketamine
Sibarov et al. Arc protein, a remnant of ancient retrovirus, forms virus-like particles, which are abundantly generated by neurons during epileptic seizures, and affects epileptic susceptibility in rodent models
Tackenberg et al. Optogenetic stimulation of VIPergic SCN neurons induces photoperiodic‐like changes in the mammalian circadian clock
AT262963B (de) Verfahren zur Herstellung von 3-Cyan-3,5,5-trimethylcyclohexanon aus Isophoron und Blausäure
PE20051163A1 (es) Formas de dosificacion oral de acido n-(2-(2-ftalimido-etoxi)-acetil)-l-alanil-d-glutamico (lk 423)
Fusco et al. Role of phosphodiesterases in Huntington’s disease
Chibly et al. Palliative care for salivary gland dysfunction highlights the need for regenerative therapies: a review on radiation and salivary gland stem cells
JP2020518547A5 (ja)
JP2024000505A5 (ja)